CYP21A2 rs121908738: Understanding Congenital Adrenal Hyperplasia
The rs121908738 variant is a genetic change located in the CYP21A2 gene, which is essential for producing the enzyme 21-hydroxylase. This variant is associated with congenital adrenal hyperplasia (CAH), a group of inherited disorders that affect the body's ability to produce specific adrenal hormones.
What each genotype means
Typical CYP21A2 function
This genotype represents the common, functional version of the CYP21A2 gene. Individuals with this profile typically produce the 21-hydroxylase enzyme at normal levels, which is necessary for proper adrenal hormone production.
This is the most common genotype found in the general population across all ancestries.
CYP21A2 carrier status
This genotype indicates you carry one copy of the variant associated with 21-hydroxylase deficiency. Carriers are typically asymptomatic, as the single functional copy of the gene is generally sufficient for normal adrenal function, though you may wish to discuss reproductive implications with a genetic counselor.
Carried by roughly 1 in 100 to 1 in 200 people, though frequencies vary significantly by ancestry.
Potential 21-hydroxylase deficiency
This genotype indicates the presence of two copies of the variant, which is associated with congenital adrenal hyperplasia (CAH). This condition can lead to impaired production of cortisol and aldosterone, potentially resulting in salt-wasting or virilization; please consult with an endocrinologist to discuss clinical monitoring and management.
This genotype is rare, occurring in approximately 1 in 10,000 to 1 in 20,000 live births globally, with higher prevalence in populations with high rates of consanguinity.
What is the rs121908738 Variant?
The rs121908738 variant is a specific alteration within the DNA sequence of the CYP21A2 gene. This gene is located on chromosome 6, within a complex region known as the human leukocyte antigen (HLA) cluster. This area of the genome is unique because it contains both the functional CYP21A2 gene and a non-functional pseudogene called CYP21A1P. Because these two sequences are highly similar, the region is prone to recombination events, where genetic material is swapped between the functional gene and the pseudogene. When this happens, the functional gene can acquire mutations that render it less effective or inactive. The rs121908738 variant is recognized in clinical databases as a pathogenic missense variant, meaning it causes a change in the protein's amino acid sequence that disrupts its normal biological function.
The Role of the CYP21A2 Gene
The CYP21A2 gene provides instructions for making an enzyme called 21-hydroxylase. This enzyme is a critical component of the adrenal glands, which are small organs located on top of the kidneys. 21-hydroxylase is responsible for converting certain steroid precursors into cortisol and aldosterone. Cortisol is vital for managing stress, maintaining blood pressure, and regulating metabolism, while aldosterone helps balance salt and water levels in the body. When the CYP21A2 gene is altered by pathogenic variants, the production of these hormones is impaired. This deficiency leads to an accumulation of precursor molecules that are instead diverted into the production of androgens, which are male-type sex hormones. This hormonal imbalance is the underlying cause of the clinical features observed in congenital adrenal hyperplasia.
Research and Clinical Associations
Research has firmly established that pathogenic variants in CYP21A2 are the primary cause of 21-hydroxylase deficiency, which accounts for approximately 95% of all congenital adrenal hyperplasia cases. The clinical presentation of CAH is broad, ranging from severe forms that cause salt-wasting crises in infancy to milder, non-classical forms that may present later in life with symptoms like virilization or subfertility. The severity of the condition is often dictated by the amount of residual enzyme activity remaining. In clinical settings, genetic testing is used to identify these variants to help clinicians understand the potential for specific health outcomes. Because CAH is an autosomal recessive condition, an individual typically needs to inherit two copies of a pathogenic variant to manifest the classic form of the disease, though compound heterozygosity—having two different pathogenic variants—is also common.
Population Frequency and Distribution
The rs121908738 variant is found across various global populations, though its frequency is relatively low. Current data indicates a carrier frequency of approximately 0.005 to 0.01 in diverse populations. This means that roughly 1 in 100 to 1 in 200 individuals may carry one copy of this variant. Because the condition is recessive, carriers typically do not show symptoms of the disorder. However, when two carriers have children, there is a statistical possibility of passing the condition to their offspring. The distribution of these variants can vary significantly based on ancestral background, reflecting the complex history of genetic inheritance in different regions of the world.
Interpreting Your Genetic Information
Understanding your genetic status regarding the CYP21A2 gene is a matter for professional medical consultation. If you have received results indicating the presence of this variant, it is important to remember that genetic testing results are not a medical diagnosis. The clinical impact of any variant depends on the specific combination of alleles inherited from both parents and the overall functional impact on the 21-hydroxylase enzyme. If you are concerned about your reproductive health or potential risks for your family, you should discuss these findings with a genetic counselor or a reproductive endocrinologist. They can provide context based on your personal and family medical history. Never make changes to your health management or medication based on genetic data without first consulting with your healthcare provider.
How common is this variant?
The carrier frequency for this variant is approximately 0.005–0.01 across diverse populations, making it a relatively rare but clinically significant finding.
Frequently asked questions
What is congenital adrenal hyperplasia?
Congenital adrenal hyperplasia (CAH) is a group of genetic disorders that affect the adrenal glands' ability to produce essential hormones like cortisol and aldosterone. It is most commonly caused by a deficiency in the 21-hydroxylase enzyme.
Is rs121908738 a diagnosis for CAH?
No, identifying a genetic variant is not a medical diagnosis. A diagnosis of CAH is made by a physician based on clinical symptoms, physical exams, and biochemical hormone testing.
What should I do if I am a carrier?
Being a carrier means you have one copy of a variant that could potentially be passed to your children. If you are planning a family, you may wish to speak with a genetic counselor to discuss reproductive options and risks.
Can this variant be treated?
CAH is managed by medical professionals through hormone replacement therapy to restore normal levels of cortisol and aldosterone. You must consult with an endocrinologist for any treatment or medication-related questions.
Sources & further reading
Educational information only, last refreshed 10/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908738?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP21A2
Pathogenic variant (p.Val282Leu) in CYP21A2 associated with non-classic congenital adrenal hyperplasia.
Pathogenic variant associated with non-classic congenital adrenal hyperplasia presenting with hyperandrogenism, oligomenorrhea, and subfertility.
Pathogenic missense variant in CYP21A2 associated with 21-hydroxylase deficiency, a cause of congenital adrenal hyperplasia.
Pathogenic variant in CYP21A2 associated with 21-hydroxylase deficiency, used in reproductive carrier screening.
Well-characterized pathogenic missense variant (p.Pro30Leu) causing non-classic congenital adrenal hyperplasia and female hyperandrogenic subfertility.
This variant in the CYP21A2 gene is involved in steroid hormone metabolism and is noted in clinical databases.